about
Immune mechanisms of protection: can adjuvants rise to the challenge?Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxA phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses.IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform.The RTS,S vaccine candidate for malaria.Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3.Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.A history of hookworm vaccine development.Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.Recent advances in recombinant protein-based malaria vaccines.Pre-erythrocytic malaria vaccines: identifying the targets.Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).Development of a schistosomiasis vaccine.TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccinesBlood-stage malaria vaccines - recent progress and future challenges.TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.Role of adjuvants in modeling the immune response.The path of malaria vaccine development: challenges and perspectives.Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.Safety, immunogenicity, and cross-species protection of a plasmid DNA encoding Plasmodium falciparum SERA5 polypeptide, microbial epitopes and chemokine genes in mice and olive baboons.Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against Plasmodium berghei.Production, quality control, stability, and potency of cGMP-produced RH5.1 protein vaccine expressed in S2 cells
P2860
Q21245319-8006A268-C99C-4871-B568-25B19C30DA63Q24273364-F72A598D-435E-41EE-A943-EF590C79389DQ28744696-CD82AE57-9FE1-46BE-A681-C7972EC9A9D8Q33776347-02D927D1-2B0A-4069-9793-D3ECEBC56430Q33979932-D1A76FCC-088F-4E3E-B925-B453967A7822Q34186762-70681AE3-7DDE-4AEA-BCF1-2B1F560B7F52Q34600955-B2AE91DA-941C-459D-B33B-D83CA3C896A2Q34606478-0E0844F9-9DBF-400B-B3BD-31E06620293CQ35138725-3A8B4F3E-A520-4C63-8A90-AE6A74C56D75Q35881296-49ADAE81-9BFE-4ABC-9D15-26E7BC10F686Q36267184-895AF0B9-089C-4918-934B-06309D8AFD4DQ36394182-50A6161F-F81B-4B55-8C98-F167C299410BQ36644236-21089630-0932-404C-8589-82771E9AD7DBQ36680084-984EB8BD-65D8-4445-A8EA-0981212FA163Q37350747-62B87221-FD7E-43B4-9A18-24909B448F07Q37384724-942C07A6-BC33-412E-952A-ED1BFDD8ED74Q37530299-F6BF6F89-744F-4A82-85D9-8B10B1B817CCQ37761208-D3CA019E-11D5-493F-906F-F735A67F490EQ37771945-72D69344-2ECA-4D13-B27F-1C5D5E5365D8Q37803320-D309A12B-32FA-4BFF-912D-0BDC3DBE56DDQ38196455-7211AB20-5766-4D88-ADBC-7775C2E4BF4BQ38718229-1BC56578-60A5-42D9-B9E9-773B9FBF4FA5Q38849255-5E545A21-31E0-4D71-82B9-EAE3949FCC08Q38886698-ADCFCBC2-A546-41E3-BEA1-AA599D1BA4A2Q41404819-15C65901-7520-44F4-B7D1-A65476451CB5Q47875209-B56CBD34-88C2-44ED-8F8D-129C83B0C38AQ56342201-E3F49399-AC50-460D-8987-129233DF17FE
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvants for malaria vaccines.
@en
Adjuvants for malaria vaccines.
@nl
type
label
Adjuvants for malaria vaccines.
@en
Adjuvants for malaria vaccines.
@nl
prefLabel
Adjuvants for malaria vaccines.
@en
Adjuvants for malaria vaccines.
@nl
P2093
P2860
P1433
P1476
Adjuvants for malaria vaccines.
@en
P2093
P2860
P304
P356
10.1111/J.1365-3024.2009.01142.X
P577
2009-09-01T00:00:00Z